Midantan tablets 100mg, No. 100

Parkinson's disease, parkinson's syndrome.

Parkinson's disease, parkinsonism syndrome: amantadine is prescribed at an initial dose of 100 mg daily for the first week, then the dose is increased to 100 mg twice a day. The required dose should be set depending on the severity of the symptoms of parksinsonism and the tolerability of the drug. Doses in excess of 200 mg per day may provide some additional benefit, but are associated with an increased risk of toxicity. Do not exceed 400 mg per day.

The daily dose should be increased gradually, at intervals of at least one week. Since patients over 65 years of age tend to have decreased renal function and, therefore, higher plasma concentrations of amantadine, these patients should be given the lowest dose that produces the desired effect.

Cancellation of amantadine should be carried out gradually, that is, reducing the dose by half with an interval of one week. Abrupt withdrawal of amantadine can aggravate the symptoms of parkinsonism, regardless of the patient's response to therapy.

1 tablet contains:

active substance :

amantadine hydrochloride - 100 mg;

Excipients:

lactose monohydrate,

starch 1500 (corn starch partially pregelatinized),

croscarmellose sodium,

talc,

stearic acid,

potato starch,

opadry II (contains: polyvinyl alcohol, partially hydrolyzed, macrogol 3350, talc, titanium dioxide E 171, aluminum varnish based on yellow quinoline E 104, iron oxide yellow E 172).

Liver failure, chronic renal failure, psychosis (including history), thyrotoxicosis, epilepsy, angle-closure glaucoma, prostatic hyperplasia, arterial hypotension, chronic heart failure stage II-III, state of agitation, preddelirium, delirious psychosis, pregnancy planning , pregnancy, lactation, concomitant administration of triamterene and hydrochlorothiazide, history of gastric or duodenal ulcer, hypersensitivity to amantadine or other components of the drug, children under 18 years of age.

Release form:

Pills

Packaging:

The package contains 100 tablets.

Composition:

1 tablet contains:

active substance :

amantadine hydrochloride - 100 mg;

Excipients:

lactose monohydrate,

starch 1500 (corn starch partially pregelatinized),

croscarmellose sodium,

talc,

stearic acid,

potato starch,

opadry II (contains: polyvinyl alcohol, partially hydrolyzed, macrogol 3350, talc, titanium dioxide E 171, aluminum varnish based on yellow quinoline E 104, iron oxide yellow E 172).

Pharmachologic effect:

Midantan is an antiparkinsonian agent, a tricyclic symmetric adamantamine.

Blocks glutamate NMDA receptors (including in the substantia nigra), thereby reducing the excessive stimulating effect of cortical glutamate neurons on the neostriatum, which develops against the background of insufficient dopamine release.

By decreasing the supply of ionized Ca 2+ to neurons, it reduces the possibility of their destruction. Mostly affects stiffness (rigidity and bradykinesia).

Indications:

Parkinson's disease, parkinson's syndrome.

Contraindications:

Liver failure, chronic renal failure, psychosis (including history), thyrotoxicosis, epilepsy, angle-closure glaucoma, prostatic hyperplasia, arterial hypotension, chronic heart failure stage II-III, state of agitation, preddelirium, delirious psychosis, pregnancy planning , pregnancy, lactation, concomitant administration of triamterene and hydrochlorothiazide, history of gastric or duodenal ulcer, hypersensitivity to amantadine or other components of the drug, children under 18 years of age.

Application during pregnancy and lactation:

Contraindicated during pregnancy (I trimester) and during lactation. Take with caution in the II and III trimesters of pregnancy.

Special instructions:

Data on the effectiveness in the treatment of extrapyramidal disorders during treatment with antipsychotic drugs (drug parkinsonism) are contradictory. The therapy should not be stopped suddenly, because a sharp exacerbation of the disease is possible. The use of ethanol while taking the drug is contraindicated.

During the period of treatment, it is necessary to refrain from driving vehicles and engaging in potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.

Method of administration and dosage:

Parkinson's disease, parkinsonism syndrome: amantadine is prescribed at an initial dose of 100 mg daily for the first week, then the dose is increased to 100 mg twice a day. The required dose should be set depending on the severity of the symptoms of parksinsonism and the tolerability of the drug. Doses in excess of 200 mg per day may provide some additional benefit, but are associated with an increased risk of toxicity. Do not exceed 400 mg per day.

The daily dose should be increased gradually, at intervals of at least one week. Since patients over 65 years of age tend to have decreased renal function and, therefore, higher plasma concentrations of amantadine, these patients should be given the lowest dose that produces the desired effect.

Cancellation of amantadine should be carried out gradually, that is, reducing the dose by half with an interval of one week. Abrupt withdrawal of amantadine can aggravate the symptoms of parkinsonism, regardless of the patient's response to therapy.

Side effects:

From the nervous system: motor or mental agitation, convulsions, headache, dizziness, irritability, insomnia, tremors, mental disorders accompanied by visual hallucinations.

From the side of the cardiovascular system: heart failure, tachycardia, orthostatic hypotension, arrhythmogenic effect.

From the digestive system: dry mouth, nausea, anorexia, dyspepsia.

From the urinary system: acute urinary retention in patients with prostatic hyperplasia, polyuria, nocturia.

Others: dermatosis, the appearance of a bluish color of the skin of the upper and lower extremities, decreased visual acuity.

Drug interactions:

Central nervous system stimulants and ethanol increase the risk of side effects. Strengthens the effect of levodopa, psychostimulants.

Compatible with central anticholinergics and other antiparkinsonian drugs.

Storage conditions:

Store in a dry place at a temperature not exceeding 25 ? C.

Shelf life:

5 years

Terms of dispensing from pharmacies:

On prescription